In a significant new development at the crossroads of health and wellness science, researchers at the University of California, San Francisco (UCSF) have published some of the first human data suggesting that psilocybin — the active compound in psychedelic mushrooms — may actively combat inflammation in the body. The findings were published in the prestigious medical journal JAMA Psychiatry on October 21, 2026.
The pilot study involved 12 participants with Parkinson’s disease, a neurodegenerative condition characterized by dysregulated inflammation and mitochondrial dysfunction. Using blood tests to measure five different inflammatory signaling molecules, researchers found that participants had significantly lower levels of inflammation following two psilocybin sessions — with improvements persisting a full month after the final dose. Markers of mitochondrial stress also showed substantial improvements immediately after treatment.
Dr. Ellen Bradley, an associate professor of psychiatry at UCSF who helped lead the analysis, described the findings as “an initial biological signal to investigate.” Co-author Aoife O’Donovan, a professor of psychiatry and behavioral sciences at UCSF, noted the findings represent “objective markers” that give researchers confidence to pursue this line of research further.
Scientists caution that the study was small and lacked a control group, but see it as a major step forward. Researchers suggest the results may have broader implications beyond Parkinson’s — potentially extending to depression, anxiety, and cardio-metabolic inflammatory disorders.
Source: NPR – New Human Data Hints at Psychedelics’ Potential to Combat Inflammation